MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial.

@article{Luisetti1996MR889AN,
  title={MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial.},
  author={M. Luisetti and C. Sturani and D. Sella and E. Madonini and V. Galavotti and G. Bruno and V. Peona and U. Kucich and G. Dagnino and J. Rosenbloom and B. Starcher and C. Grassi},
  journal={The European respiratory journal},
  year={1996},
  volume={9 7},
  pages={
          1482-6
        }
}
  • M. Luisetti, C. Sturani, +9 authors C. Grassi
  • Published 1996
  • Medicine
  • The European respiratory journal
  • We investigated whether MR889, a synthetic cyclic thiolic elastase inhibitor, administered for a period of 4 weeks to chronic obstructive pulmonary disease (COPD) patients, is well-tolerated, and whether it modifies biochemical indices of lung destruction. The study was a double-blind, randomized, placebo-controlled clinical trial in COPD patients. Thirty subjects were administered MR889 orally at a dose of 500 mg b.i.d. for 4 weeks, and 30 received placebo following the same schedule. In… CONTINUE READING
    Current synthetic inhibitors of human neutrophil elastase in 2005
    15

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 31 REFERENCES
    Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis.
    375
    The potential role of elastase inhibitors in emphysema treatment.
    14
    The specific treatment of emphysema.
    5
    Measurement of urinary desmosine as an indicator of acute pulmonary disease.
    35